This page shows the latest Triple negative breast cancer news and features for those working in and with pharma, biotech and healthcare.
Trodelvy is currently approved in more than 40 countries for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or ... help bring Trodelvy to more people living with
Specifically, NICE’s recommends Keytruda as an option with chemotherapy for neoadjuvant, and alone as adjuvant treatment after surgery for patients with early triple-negative or locally advanced breast cancer. ... The decision marks the first time
Commenting on the FDA’s decision, Bill Grossman, senior vice president, therapeutic area head, Gilead Oncology, said: “Trodelvy has already changed the treatment landscape in second-line metastatic triple-negative breast ... Trodelvy is approved in
Women diagnosed with cases of early triple-negative breast cancer (TNBC) where the disease had not progressed beyond the breast and lymph nodes – markers in stage 2 and 3 – were treated ... pre-operative chemotherapy increases the treatment response
European patients with metastatic triple-negative breast cancer can now receive the antibody-drug conjugate as second-line monotherapy. ... The therapy is now indicated as monotherapy for the treatment of adults with unresectable (cannot be removed by
O’Day also focused on the company’s oncology drugs and said: “Our marketed portfolio continues to expand with four new country approvals for Trodelvy for metastatic triple-negative breast cancer, ... Sales of Tecartus (brexucabtagene autoleucel)
More from news
Approximately 10 fully matching, plus 82 partially matching documents found.
Take a trial for triple negative breast cancer, for example, that was done predominantly on white women when it disproportionately affects black women.
For example, a few years back we created clinical trial advertising materials for a Triple Negative Breast Cancer study project and, as the condition adversely impacts the black population, we made ... opportunities.”. A blood cancer charity recently
9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... Tucatinib is currently being
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug conjugate
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
The shocking stats surrounding black women and health outcomes. Alarmingly, although black women are overall less likely to develop breast cancer, they’re 40% more likely to die from it compared ... Black women are at higher risk for a type of
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...